Drug Database
FE

fenofibrate (Triglide)

✓ Approved

SkyePharma PLC · PPARA · 小分子

什么是 fenofibrate?

fenofibrate 是一种小分子,由SkyePharma PLC研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Triglide
公司SkyePharma PLC
药物类别小分子
分子靶点PPARA
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

fenofibrate 作用于 1 个分子靶点:

PPARAperoxisome proliferator activated receptor alpha (NR1C1, PPAR-alpha)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

fenofibrate 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Metabolism and nutrition disordersHypertriglyceridaemia✓ Approved
Metabolism and nutrition disordersDyslipidaemia✓ Approved

相关研究文献

PubMedCommunications biology2026-11-19

ALDH2 inhibition reprograms tubular epithelial cell metabolism and promotes renal injury susceptibility.

Guo Jialin J, Xu Fengyang F, Ma Jiaxin J, Guo Yunyun Y et al.

Fatty Acid Oxidation (FAO) dysfunction induces pro-fibrotic transition in tubular epithelial cells (TECs) and contributes to renal fibrosis in chronic kidney disease (CKD); however, the drivers of metabolic reprogramming in TECs remain unclear. We investigate the role of aldehyde dehydrogenase 2 (ALDH2) in FAO using human cohorts, renal tubular Aldh2 knockout mice, Aldh2 rs671 variant mice, and primary TECs, combined with pharmacological and molecular assays. In this work, we find that ALDH2 is downregulated in the injured proximal tubular cells and inversely correlated with lipid deposition and renal fibrosis in CKD patients and mouse models. ALDH2 deletion impairs FAO, leading to lipid deposition and aggravates renal fibrosis following kidney injury, driven by suppression of the key transcription factor PPARα/RXRα complex and its downstream FAO targets, particularly CPT1α. Moreover, ALDH2 deficiency blunts the PPARα agonist Fenofibrate-induced FAO activation and renoprotection. These findings reveal that ALDH2 acts as a mediator of FAO in TECs, making it a potential therapeutic target for CKD.

PMID 43052355
阅读全文 →
PubMedSingapore medical journal2026-11-16

Comments on: suboptimal response to ursodeoxycholic acid among patients with primary biliary cholangitis and fenofibrate as add-on therapy: a single-centre retrospective study.

Ghayas Mavia M, Rizvi Syed Minhal Hussain SMH, Shakeel Munir M, Munadillah et al.

PMID 43037122
阅读全文 →
PubMedAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026-11-16

An APOA5-Derived Signature Bridges Cholesterol Homeostasis to T-Cell Exhaustion and Directs Lung Adenocarcinoma Immunotherapy Response.

Deng Min M, Su Sek Man SM, Zhai Zhiran Z, An Tingting T et al.

Immune heterogeneity and metabolic remodeling frequently limit the efficacy of immunotherapy in lung adenocarcinoma (LUAD). To address this challenge, we integrated single-cell and bulk RNA sequencing analyses, pairing machine learning with preclinical models to develop the APOA5-correlated T-cell Signature (ACTsig), which effectively stratifies LUAD patients and predicts immunotherapeutic response. Moreover, We identified apolipoprotein A-V (APOA5) as a previously unrecognized tumor suppressor linking cholesterol homeostasis to the tumor immune ecosystem. Mechanistically, APOA5 deficiency induced intracellular cholesterol accumulation and MIF production. Cholesterol depletion and replenishment established a causal role for cholesterol accumulation in regulating MIF production, while MIF knockdown reversed APOA5-loss-induced T-cell exhaustion and recombinant MIF restored the phenotype. Meanwhile, CXCR4 blockade rescued APOA5-loss-induced T-cell exhaustion, supporting the functional involvement of the MIF receptor CXCR4 in this immunosuppressive phenotype. Finally, in silico drug screening identified fenofibrate, which, in combination with anti-PD-1 therapy, significantly suppressed tumor growth in APOA5-deficient models. Together, these findings establish ACTsig as a predictive biomarker for immunotherapy response and reveal an APOA5-cholesterol-MIF-CXCR4 axis underlying T-cell exhaustion.

PMID 43036274
阅读全文 →
PubMedDiabetes research and clinical practice2026-11-15

Fenofibrate and diabetic retinopathy: an updated systematic review and meta-analysis of randomized controlled trials.

Dogru Edhem E, Chavez Matheus Pedrotti MP, Toth Otávio O, Nasserdine Dalyl D et al.

To assess fenofibrate effects on diabetic retinopathy (DR) progression and need for retinal treatment. PubMed, Embase, and Scopus were searched through June 9, 2026, for randomized trials comparing oral fenofibrate with placebo in adults with type 1 or type 2 diabetes and at least two years of follow-up. The primary outcome was a composite of DR progression or need for retinal treatment. Odds ratios (OR) were pooled using random-effects models. Four trials (20,655 participants) were included; three (3,756) contributed to the primary outcome. Fenofibrate reduced the composite outcome (OR 0.67, 95% CI 0.56-0.81; I2 = 0%), incident macular edema (0.47, 0.29-0.76; I2 = 0%) and need for retinal laser (0.75, 0.65-0.87; I2 = 7%). DR progression on imaging was reduced (0.72, 0.58-0.89; I2 = 0%), but not when FIELD one-step progression was used (0.80, 0.60-1.07). Moderate vision loss (0.99, 0.83-1.18; I2 = 0%) and all-cause mortality (1.01, 0.87-1.17; I2 = 26%) did not differ. Subgroup analyses by diabetes type and baseline retinopathy were underpowered. Fenofibrate reduces the composite of DR progression or need for retinal treatment over up to five years of follow-up, without a demonstrated effect on moderate vision loss.

PMID 43034021
阅读全文 →
PubMedBrain research2026-11-15

Impact of PPAR agonists on seizure suppression to disease modification using status-epilepticus experimental model: Role of the PPAR in metabolic-inflammatory pathway.

Sinha Surabhi S, Sarangi Sudhir Chandra SC, Sharma Deeksha D, Pattnaik Soumya Sucharita SS et al.

This study explored the potential of peroxisome proliferator-activated receptor (α/γ) (PPAR modulators) for seizure control and the consequences of status epilepticus (SE) due to their anti-inflammatory and neuro-modulatory properties. A lithium-pilocarpine-induced status epilepticus (SE) model in Wistar rats determined the optimal dose of PPAR modulators (fenofibrate, pemafibrate, and saroglitazar) for seizure suppression. Based on seizure parameters, an efficacy study examined PPAR modulators alone and in combination with ASMs (valproate and perampanel). Evaluations of disease-modifying effects included neurobehavioral tests, electron microscopy for neurodegeneration, immunohistochemistry (NeuN for neuronal viability and GFAP for astrocytosis), Western blotting for PPARα, HMGCS2, NLRP3, and mTOR, and ELISA for antioxidant capacity and neuroinflammatory biomarkers. The optimal doses of fenofibrate, pemafibrate, and saroglitazar were 200, 1.5, and 3 mg/kg, respectively. Compared with the SE-control group, drug-treated groups had higher latency (p<0.001), a lower number and percentage of rats with stage 3-4 seizures (p=0.003, for both), better memory retention (p=0.001), less myelin-sheath/axonal damage (p<0.001), significant differences in protein expressions [NeuN, PPARα, HMGCS2, mTOR, and NLRP3 (p<0.001)], and less neuroinflammation. The PPAR modulators + perampanel group had no stage 3-4 seizures. Compared to valproate alone, fenofibrate+valproate exhibited less neurodegeneration and astrocytosis in the hippocampus and cerebral cortex (p<0.001, for all). All PPAR modulator combinations with ASM groups had significantly higher PPARα and HMGCS2 expression. PPAR modulators fenofibrate, pemafibrate, and saroglitazar have similar seizure-control potential. In the SE model, PPAR modulators with ASM showed significant neuroprotection and increased PPARα expression compared to ASM alone.

PMID 43033961
阅读全文 →
PubMedJournal of clinical lipidology2026-11-15

Ocular manifestations of lipid disorders: Clinical clues for lipidologists narrative review.

Varghese Ron T RT

Lipid disorders can produce recognizable findings in the eyelids, cornea, lens, and retina. Although many are nonspecific, selected phenotypes may signal severe hypercholesterolemia, chylomicronemia, or an inherited disorder of lipid metabolism. PubMed was searched from inception through August 31, 2026, using terms related to dyslipidemia, inherited lipid disorders, and ocular phenotypes. English-language human studies, clinical guidance, randomized trials, systematic reviews, cohort studies, and phenotype-defining case series were prioritized. As this was a narrative review, formal preferred reporting items for systematic reviews and meta-analyses screening, duplicate selection, risk-of-bias assessment, and meta-analysis were not performed. Clinically informative findings include xanthelasma, premature corneal arcus, lipemia retinalis, retinal hard exudates, diffuse corneal opacity with very low high-density lipoprotein cholesterol, juvenile cataracts, and pigmentary retinopathy with very low apolipoprotein B. Xanthelasma and corneal arcus may support evaluation but are not independent cardiovascular risk markers. Lipemia retinalis indicates severe chylomicronemia and should prompt assessment of pancreatitis risk. Less common phenotypes may suggest lecithin-cholesterol acyltransferase deficiency, Schnyder corneal dystrophy, cerebrotendinous xanthomatosis, or abetalipoproteinemia. Randomized trials indicate that fenofibrate can slow early diabetic retinal disease progression, although it does not replace established ophthalmic treatment. Ocular examination can provide accessible evidence of systemic lipid disturbance. Clinical value lies in distinguishing common nonspecific findings from phenotypes suggesting severe hypertriglyceridemia, possible familial hypercholesterolemia, acute retinal vascular disease, or rare inherited lipid disorders.

PMID 43034116
阅读全文 →

注册免费账户还可查看另外 4330 篇文献

免费注册查看全部文献 →

了解更多fenofibrate